Studies in human malaria; the protective and therapeutic action of quinacrine against St. Elizabeth strain vivax malaria.

During the process of testing antimalarial compounds in prisoner volunteers at Atlanta, GA (Coatney et al, 1948a), it was necessary to define under the conditions of our test, the maximum effect to be expected from quinacrine (atabrine) in terms of prevention or cure of sporozoite-induced St. Elizabeth strain vivax malaria. A relatively low suppressive dosage of quinacrine (0.1 gram daily) has been employed in earlier tests (Coatney et al, 1947) but the information obtained did not provide an adequate basis for comparison with new drugs, which were being tested at near-toxic dosages.

Full text article: https://academic.oup.com/aje/article-abstract/49/1/25/112573?redirectedF...